TY - JOUR
T1 - The impact of the boston ocular surface prosthesis on wavefront higher-order aberrations
AU - Gumus, Koray
AU - Gire, Anisa
AU - Pflugfelder, Stephen C.
N1 - Funding Information:
Publication of this article was supported by Grant EY11915 (S.C.P.) from the National Institutes of Health , Bethesda, Maryland; an unrestricted grant from Research to Prevent Blindness, Inc , New York, New York; the Oshman Foundation , Houston, Texas; the William Stamps Farish Fund , Houston, Texas; Hamill Foundation , Houston, Texas; and the Scientific and Technological Research Council of Turkey, Ankara, Turkey (KG). Dr Pflugfelder is a consultant for Alcon, Allergan, and Glaxo SmithKline. He serves on the speakers bureaus of Allergan and Alcon and receives research grants from Allergan , Inspire , and Glaxo SmithKine . The other authors have no financial interests to disclose. Involved in Design and conduct of study (S.C.P., K.G.); Collection of data (S.C.P., K.G., A.G.); Management (K.G., S.C.P.), analysis (K.G., S.C.P.), and interpretation (K.G., S.C.P., A.G.) of the data; and Preparation, review, and approval of the manuscript (K.G., S.C.P.). This study was approved by the Baylor College of Medicine, Institutional Review Board. The research protocol adhered to the tenets of the Declaration of Helsinki for clinical research. Written informed consent was obtained from all the participants after explanation of the purpose and possible consequences of the study. The authors have had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.
PY - 2011/4
Y1 - 2011/4
N2 - Purpose: To evaluate the effect of the Boston Ocular Surface Prosthesis (Boston Foundation for Sight) on higher-order wavefront aberrations in eyes with keratoconus, eyes that have undergone penetrating keratoplasty, eyes that have undergone refractive surgery, and eyes with ocular surface diseases. Design Prospective, clinical study. Methods The study evaluated 56 eyes of 39 patients with irregular astigmatism who were treated with the Boston Ocular Surface Prosthesis when conventional treatments failed. Patients were sorted into 4 clinical groups based on the underlying cause of irregular astigmatism, including keratoconus (group 1), postpenetrating keratoplasty (group 2), postrefractive surgery (group 3), and ocular surface diseases (group 4). Another 6 eyes of 5 patients who were treated with rigid gas permeable lenses also were evaluated. Best-corrected visual acuity; topographic refractive indices, including spherical, cylindrical, spherical equivalent values; and higher-order and total wavefront aberration errors were noted at baseline and after fitting the lens. Results In all groups, higher-order wavefront aberration error was noted to decrease significantly in eyes wearing the Boston Ocular Surface Prosthesis (P < .001, P = .001, P = .002, and P = .001, respectively). By post hoc analysis, significant differences in the level of higher-order aberrations were observed only between groups 1 and 4 (P = .012) and groups 1 and 2 (P = .033). In the overall group, mean correction rate of higher-order aberration error with the Boston Ocular Surface Prosthesis was 72.3%. However, in eyes with rigid gas permeable lenses, 2 eyes demonstrated increased higher-order aberration error, whereas the mean correction rate in other 4 eyes was only 42.5%. Conclusions With its unique structure, the Boston Ocular Surface Prosthesis was found to be very effective in reducing higher-order wavefront aberrations in patients with irregular astigmatism resulting from a number of corneal and ocular surface conditions who had not responded satisfactorily to conventional methods of optical correction.
AB - Purpose: To evaluate the effect of the Boston Ocular Surface Prosthesis (Boston Foundation for Sight) on higher-order wavefront aberrations in eyes with keratoconus, eyes that have undergone penetrating keratoplasty, eyes that have undergone refractive surgery, and eyes with ocular surface diseases. Design Prospective, clinical study. Methods The study evaluated 56 eyes of 39 patients with irregular astigmatism who were treated with the Boston Ocular Surface Prosthesis when conventional treatments failed. Patients were sorted into 4 clinical groups based on the underlying cause of irregular astigmatism, including keratoconus (group 1), postpenetrating keratoplasty (group 2), postrefractive surgery (group 3), and ocular surface diseases (group 4). Another 6 eyes of 5 patients who were treated with rigid gas permeable lenses also were evaluated. Best-corrected visual acuity; topographic refractive indices, including spherical, cylindrical, spherical equivalent values; and higher-order and total wavefront aberration errors were noted at baseline and after fitting the lens. Results In all groups, higher-order wavefront aberration error was noted to decrease significantly in eyes wearing the Boston Ocular Surface Prosthesis (P < .001, P = .001, P = .002, and P = .001, respectively). By post hoc analysis, significant differences in the level of higher-order aberrations were observed only between groups 1 and 4 (P = .012) and groups 1 and 2 (P = .033). In the overall group, mean correction rate of higher-order aberration error with the Boston Ocular Surface Prosthesis was 72.3%. However, in eyes with rigid gas permeable lenses, 2 eyes demonstrated increased higher-order aberration error, whereas the mean correction rate in other 4 eyes was only 42.5%. Conclusions With its unique structure, the Boston Ocular Surface Prosthesis was found to be very effective in reducing higher-order wavefront aberrations in patients with irregular astigmatism resulting from a number of corneal and ocular surface conditions who had not responded satisfactorily to conventional methods of optical correction.
UR - http://www.scopus.com/inward/record.url?scp=79952985645&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=79952985645&partnerID=8YFLogxK
U2 - 10.1016/j.ajo.2010.10.027
DO - 10.1016/j.ajo.2010.10.027
M3 - Article
C2 - 21269603
AN - SCOPUS:79952985645
SN - 0002-9394
VL - 151
SP - 682-690.e2
JO - American journal of ophthalmology
JF - American journal of ophthalmology
IS - 4
ER -